Referências

1. Anvisa. Bula de Entresto® para profissionais da saúde. Disponível em https://consultas.anvisa.gov.br/#/bulario/q/?numeroRegistro=100681141. Acesso em junho de 2022. 2. Polónia J, Gonçalves FR. The historical evolution of knowledge of the involvement of neurohormonal systems in the pathophysiology and treatment of heart failure. Rev Port Cardiol (Engl Ed). 2019 Dec;38(12):883-895. 3. Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. JACC Heart Fail. 2020 Oct;8(10):800-810. 4. McMurray JJV, Packer M, Akshay SD, et al; PARADIGM-HF Investigators and Committee. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371:993-1004. 5. Desai AS, McMurray JJ, Packer M, et al. Effect of theangiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. (2015) 36:1990–7. 6. Packer M, McMurray JJ, Desai AS, et al; PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015 Jan 6;131(1):54-61. 7. Zile MR, Claggett BL, Prescott MF, et al. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol. 2016 Dec 6;68(22):2425-2436. 8. Damman K, Gori M, Claggett B, et al. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC Heart Fail. 2018 Jun;6(6):489-498. 9. Chandra, Alvin, et al. "Effects of sacubitril/valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial." JAMA cardiology 3.6 (2018): 498-505. 10. Lewis, Eldrin F., et al. "Health-related quality of life outcomes in PARADIGM-HF." Circulation: Heart Failure 10.8 (2017): e003430. 11. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003 Sep 6;362(9386):772-6. 12. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991 Aug 1;325(5):293-302. 13. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001 Dec 6;345(23):1667-75. 14. Wachter R, Senni M, Belohlavek J, et al.; TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019 Aug;21(8):998-1007. 15. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 Feb 7;380(6):539-548. 16. Claggett, Brian, et al. "Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan." New England Journal of Medicine 373.23 (2015): 2289-2290. 17. Heidenreich P, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. null2022, 0 (0). 18. McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. 19. Marcondes-Braga FG, Moura LAZ, Issa VS, et al. Emerging Topics Update of the Brazilian Heart Failure Guideline - 2021. Atualização de Tópicos Emergentes da Diretriz Brasileira de Insuficiência Cardíaca – 2021. Arq Bras Cardiol. 2021;116(6):1174-1212. 20. Ministério da Saúde. Conitec- Sacubitril/valsartana para o tratamento de pacientes adultos com insuficiência cardíaca crônica sintomática (NYHA classe II-IV) com fração de ejeção reduzida. Disponível em http://conitec.gov.br/images/Relatorios/2019/Relatorio_Sacubitril_Valsartana_ICC_FINAL_454_2019.pdf. Acesso em abril de 2022. 21. Ministério da Saúde. Diretrizes brasileiras para diagnóstico e tratamento da insuficiência cardíaca com fração de ejeção reduzida. Disponível em https://www.gov.br/saude/pt-br/assuntos/protocolos-clinicos-e-diretrizes-terapeuticas-pcdt/arquivos/2021/portaria-conjunta-17_18_11_2020_diretrizes-brasileiras-icfer__-1.pdf. Acesso em abril de 2022.